Indivior is in an execution phase centered on expanding SUBLOCADE while still relying heavily on buprenorphine-based sublingual products, including SUBOXONE Tablet and SUBUTEX Tablet; it also remains dependent on third-party contract manufacturers.
The filing accelerates the exit from Reckitt’s tablet manufacturing, but does not yet complete the replacement. Indivior and Reckitt agreed to move the Copacker Supply Agreement’s termination date to January 15, 2027, with Reckitt producing additional units before then. 〔0〕 This removes a legacy supply relationship sooner than previously scheduled, but the new supplier’s obligations become enforceable only after its manufacturing process is validated. 〔1〕
The financial burden is contained; the operational risk is the unresolved piece. Indivior will cover volume shortfall, asset disposal, depreciation recovery, redundancy, incentive, and potential third-party costs, but the filing says those costs are fixed or capped and immaterial. 〔2〕 That makes this less a near-term earnings event than a supply-continuity transition: the company has identified a replacement, but has not yet demonstrated that the replacement is fully validated and ready.
Bottom line: This is a strategically sensible cleanup of a legacy manufacturing arrangement, but it adds a short-term execution checkpoint around validation. It changes the supply-chain setup more than the financial outlook today.
Read the original 8-K on SEC EDGAR ↗